Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2020-03-26 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于2019年度股东大会增加临时提案暨股东大会补充通知的公告
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the 2019 Annual General Meeting (AGM) of 华兰生物工程股份有限公司. It includes information about the addition of a temporary proposal, the schedule and procedures for the AGM, voting instructions, and proxy forms. The content focuses on the organization and conduct of the AGM, including agenda items to be voted on, voting methods (on-site and online), and legal compliance. There are no financial statements or detailed financial performance data included, nor is this a transcript or a report of results. The document is not a simple announcement of a report publication but a comprehensive notice related to the AGM itself. Therefore, it fits the category of AGM Information (AGM-R).
2020-03-26 Chinese
独立董事对第七届董事会第六次会议的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent directors' opinion report related to various corporate governance matters including related party transactions, external guarantees, internal control evaluation, appointment of the audit firm for the next fiscal year, investment and financing matters, profit distribution and capital reserve conversion plans, and nomination of independent directors. It references compliance with company law, securities regulations, and governance guidelines. The content is focused on independent directors' opinions and confirmations rather than presenting full financial statements or audit reports. The document length is 2630 characters, which is relatively short and more consistent with an opinion or governance-related report rather than a full annual report or audit report. It does not contain detailed financial data or audit results but rather independent directors' assessments and approvals. Therefore, the document best fits the category of Audit Report / Information (AR) as it includes independent directors' opinions on audit-related matters and internal control evaluations, but is not a full annual report or standalone audit report itself. It is not a simple announcement or certification, so Regulatory Filings (RNS) is less appropriate. Hence, the classification is AR with high confidence. FY 2019
2020-03-23 Chinese
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding the use of funds by controlling shareholders and related parties for the fiscal year ending December 31, 2019. It references an audit report issued by Da Hua Certified Public Accountants with an unqualified opinion on the 2019 financial statements. The document includes detailed tables summarizing non-operating fund occupation and related party transactions. It is issued pursuant to regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding disclosure of related party fund usage. The document is not a full annual report or audit report itself but a specialized audit-related explanatory statement focusing on related party fund occupation. It contains substantive financial data and audit verification but is distinct from a full annual report or standalone audit report. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone audit-related disclosure focusing on a specific audit matter (related party fund occupation) and includes audit procedures and findings. The document length (6300 characters) and content support it being a detailed audit information report rather than a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2019
2020-03-23 Chinese
关于用自有资金进行投资理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 华兰生物工程股份有限公司 regarding the company's decision to use up to 30 billion yuan of its own funds for investment and financial management. It details the investment purpose, amount, objects, approval procedures, impact on the company, risk control measures, and independent directors' opinions. The document is a formal announcement about a capital management decision rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data but rather describes a financing or capital usage update. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (1469 characters), and it is not merely announcing a report publication but providing substantive information about the investment plan.
2020-03-23 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to audit operations, information disclosure, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or internal control checklist rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings such as audit reports or annual reports. It is also not an announcement or presentation but an internal control compliance document. Given the nature of the content focusing on internal control rules and their implementation, this fits best under Regulatory Filings (RNS) as a general compliance document that does not fit other specific categories.
2020-03-23 Chinese
独立董事2019年度述职报告（田莉军）
Management Reports Classification · 95% confidence The document is titled as an "Independent Director 2019 Annual Work Report" for a company, detailing the independent director's activities, opinions on various company matters including internal control, audit firm appointment, investment, profit distribution, accounting policy changes, and board candidate nominations during the 2019 fiscal year. It references compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The content is a detailed report of the independent director's duties and opinions for the year 2019, which aligns with a Management Reports (MDA) filing type, as it provides management's detailed explanation and opinions on company governance and financial matters. It is not an announcement or a brief summary but a substantive report. Therefore, the appropriate classification is Management Reports (MDA).
2020-03-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.